Skip to content

Clinical effect of Y combined with radioactive particle chain brachytherapy in the treatment of Klaskin tumor.

Clinical effect of Y combined with radioactive particle chain brachytherapy in the treatment of Klaskin tumor.

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-OON-15006655
Enrollment
Unknown
Registered
2015-06-26
Start date
2015-07-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Klaskin tumor

Interventions

A:Biliary drainage
B:Biliary drainage and biliary Y- stent implantation
C:Bile duct stent plus particle chain brachytherapy

Sponsors

The First Affiliated Hospital of Zhangzhou University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1. aged 18 years old (male or female) 2. histology and cytology confirmed 3. More than 3 hours, liver function Child grade B 4. there is evidence of typical imaging (ultrasound, CT, MRCP, PTC angiography) 5. the expected survival time over 12 weeks In blood and liver function examination basically normal, neutrophil 1.0*10^9/L, platelet > 9* 10^9/L, serum bilirubin efficiency of 15 times the upper limit of normal value; without liver metastasis. The levels of ALT and AST is less than 15 times the upper limit of normal value; coagulation function is basic and normal, no activity of bleeding tendency; 7. the KPS score >60.

Exclusion criteria

Exclusion criteria: 1. the constitution of the patients is too weak, can not be tolerated or unwilling to accept operation; 2. complicated with other malignant tumors; 3. serious heart and lung dysfunction, intolerance to percutaneous operation; 4. serious disease (diabetes and blood coagulation dysfunction) patients; 5. tumor puncture site bleeding, necrosis; 6. pregnant, lactating women and all single and nonparous young patients; 7. contrast agent, local anesthetic allergy.

Design outcomes

Primary

MeasureTime frame
Length of biliary tract stricture;Bile duct stricture;

Countries

China

Contacts

Public ContactHanxinwei
hanxinwei2006@163.com+86 13503842129

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026